MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Npj Digital Medicine

  • August 15, 2026
Advancing Artificial Intelligence in Healthcare: Key Policy Focus Areas from the 2025 HHS Information Request
  • David C. Klonoff
  • Agatha F. Scheideman
  • Mandy M. Shao
  • Juan Espinoza
  • August 15, 2026
  1. The HHS RFI seeks public feedback on AI integration in healthcare, focusing on regulation, reimbursement, and research enhancements.
  2. Key conclusions from the HHS guidance include fostering an industry-friendly regulatory framework and ensuring patient protections.
  3. AI applications in clinical care include tools for risk prediction, clinical decision support, medication management, and patient engagement.
  4. The RFI identifies diabetes as a case study for AI advancements, aiming to improve regulatory frameworks and reimbursement structures.
  5. Stakeholder feedback on the RFI is crucial for shaping future HHS policies on AI integration in healthcare by the February 23, 2026 deadline.
...more

Food Safety And Risk

  • August 15, 2026
Novel Active Edible Coating Utilizing Safflower (Carthamus tinctorius L.) Extract for Microbial Control and Prolonged Shelf Life of Cheese
  • Elif Ayça Güler
  • Elif Özbey
  • August 15, 2026
  1. Approximately one-third of food produced globally is lost or wasted annually during handling, storage, and transportation.
  2. Conventional petroleum-based packaging raises environmental concerns due to poor biodegradability and waste accumulation.
  3. Active edible coatings, such as those containing safflower extract, release bioactive compounds to manage microbial spoilage and oxidative deterioration.
  4. Edible coatings can enhance food quality and shelf life by acting as protective barriers that reduce moisture loss and preserve aroma.
  5. The application of edible coatings employs various techniques, with dipping being the most common for uniform coverage on food surfaces.
...more

Acta Neurochirurgica

  • August 15, 2026
Reply to: Methodological Issues in the Structural Analysis of Chiari Malformation Type 0
  • B. Candan
  • B. Ozkal
  • E. Top
  • August 15, 2026
  1. The classification of Chiari malformation type 0 (CM-0) is not universally recognized and is characterized by Chiari-like symptoms and minimal tonsillar descent.
  2. The study aimed to assess a broader range of CM-0 patients rather than replicate studies focusing solely on those with syringomyelia.
  3. None of the observed morphometric differences between CM-0 patients and controls achieved statistical significance after corrections for multiple comparisons.
  4. The authors acknowledge limitations in their study, including reliance on two-dimensional measurements and lack of standardized cerebrospinal fluid flow studies.
  5. Future research should explore morphometry, cerebrospinal fluid dynamics, and symptomatology to better understand the CM-0 classification.
...more

MDSpire News

  • August 14, 2026
FDA approves tau PET imaging agent
  • Kathryn Wighton
  • August 14, 2026
  • 2 min

Objective: To report the FDA approval of florquinitau F18 injection (TAUKLARIFY) for tau PET imaging in adults with cognitive impairment undergoing evaluation f

...more
2 min

MDSpire News

  • August 14, 2026
FDA approves iberdomide for multiple myeloma
  • Kathryn Wighton
  • August 14, 2026
  • 3 min
  1. The FDA granted accelerated approval to iberdomide for adults with multiple myeloma who had prior therapy including a proteasome inhibitor and an immunomodulatory agent.
  2. Iberdomide is the first cereblon E3 ligase modulator approved by the FDA and is part of the cereblon-modulating protein degrader class.
  3. The approval was based on the phase 3 EXCALIBER-RRMM trial, which compared iberdomide with daratumumab and dexamethasone to a standard regimen.
  4. At 16 months, 41% of patients receiving the iberdomide regimen achieved MRD-negative complete response compared to 21% in the control group.
  5. Iberdomide has serious adverse reactions, including pneumonia and infections, and carries boxed warnings for embryo-fetal toxicity and thromboembolism.
...more

Phoenix Children's Medical Connection

  • August 14, 2026
American Epilepsy Society Clinical Practice Guideline: Infantile Epilepsy
  • August 14, 2026
  • 2 min

Objective: To provide updated, evidence-based recommendations for the management of epilepsy in infants and children aged 1 month to Approach: Guideline Develop

...more
2 min

Phoenix Children's Medical Connection

  • August 14, 2026
De Novo Variants in the Splicing Factor Gene SF3B1 Are Associated with Neurodevelopmental Disorders
  • August 14, 2026
  • 2 min
  1. Constitutional variants in the splicing factor SF3B1 are linked to neurodevelopmental disorders for the first time.
  2. A cohort of 26 individuals with developmental delays exhibited SF3B1 constitutional heterozygous variants, mostly de novo.
  3. The variants included loss-of-function (n=9) and missense variants (n=17), with missense variants linked to more severe phenotypes.
  4. Functional assays showed that de novo missense variants subtly altered splicing without causing complete loss of SF3B1 function.
  5. The findings suggest SF3B1 should be considered in diagnostic algorithms for children with unexplained developmental issues.
...more

Phoenix Children's Medical Connection

  • August 14, 2026
International Consensus on the Evaluation and Management of : Results From a Modified Delphi Survey
  • August 14, 2026
  • 2 min

Objective: To establish best-practice recommendations for the diagnosis, evaluation, and management of hypothalamic hamartomas (HH) through expert consensus. Ap

...more
1 min

Baptist Health South Florida

  • August 14, 2026
Updated ASTRO Guideline Reflects a New Era for Radiation Therapy in Pancreatic Cancer
  • August 14, 2026
  • 6 min

Objective: To update clinical practice guidelines for radiation therapy in pancreatic cancer, incorporating recent evidence and expanding recommendations. Appro

...more

MDSpire News

  • August 14, 2026
DOJ targets alleged $95M wound fraud
  • Kathryn Wighton
  • August 14, 2026
  • 2 min
  1. Stephen Dubin, MD, allegedly caused over $95 million in Medicare claims for unnecessary amniotic wound allografts.
  2. Prosecutors claim Dubin received illegal kickbacks, bribes, and rebates from distributors influencing his decisions.
  3. The indictment alleges falsification of patient records to make procedures appear compliant with Medicare requirements.
  4. Dubin faces one conspiracy charge and five health care fraud counts, with a potential maximum sentence of 60 years.
  5. This case marks the first charges announced in Nevada by the Justice Department's West Coast Health Care Fraud Strike Force.
...more

Compendium

  • August 14, 2026
Premier Dental Products to Distribute PerioStōm® for Post-Procedural Periodontal Care
  • News Staff
  • August 14, 2026
  • 2 min

Objective: To announce the exclusive distribution partnership between Premier Dental Products and Forward Science for the PerioStōm® product. Approach: Distribu

...more

The Medicine Maker

  • August 14, 2026
Musings from The Power List: John Maher
  • John Maher
  • August 14, 2026
  • 5 min
  1. John Maher's highlight was opening the AERIAL phase 1/2 trial for LEU011, an autologous CAR T-cell therapy for solid tumors.
  2. The main bottleneck in cell and gene therapy is delivery, with issues in manufacturing complexity, cost, and logistics.
  3. Progress in understanding therapy failures includes insights into resistance, antigen escape, and tumor microenvironment suppression.
  4. Regulatory decisions impact the cost and access of therapies, shaping their development and delivery despite not controlling prices.
  5. Successful cell and gene therapy programs must focus on scalable manufacturing, efficient delivery, and early engagement with stakeholders.
...more

The Pathologist

  • August 14, 2026
AI in Pathology Education: Learning as We Go
  • Deeksha Sikri
  • August 14, 2026
  • 6 min
  1. Social media in pathology fostered a community that accelerated collaboration and idea exchange, leading to the development of guidelines.
  2. AI's integration into medical education is driven by individual curiosity rather than a coordinated rollout, creating a unique learning environment.
  3. Educators must define objectives and gather context before utilizing AI tools to enhance learning, similar to the approach in pathology.
  4. AI can assist in educational tasks, but the responsibility for clinical reasoning and judgment remains with the educators.
  5. The current AI moment in education presents an opportunity for educators to engage thoughtfully and shape its impact on learning.
...more

The Pathologist

  • August 14, 2026
UK Report Signals Forensic Staffing Crisis
  • August 14, 2026
  • 3 min
  1. The Royal College of Pathologists report highlights workforce shortages and an aging consultant workforce in UK forensic pathology services.
  2. Consultant numbers in forensic pathology have remained largely unchanged over the past decade despite increasing workloads and case complexity.
  3. The report indicates that 30 percent of the consultant workforce is expected to retire within the next decade, with only 10 residents currently training.
  4. Respondents reported an average workweek of 42 hours, with significant time spent on administration and postmortem examinations.
  5. The report recommends coordinated workforce planning and expanding training capacity to address the challenges faced by forensic pathology services.
...more

The Ophthalmologist

  • August 14, 2026
Combination Therapy in Myopia Control
  • Jan Roelof Polling
  • Trine Møldrup Jakobsen
  • Leila Sara Eppenberger
  • Andrzej Grzybowski
  • August 14, 2026
  • 9 min
  1. Combination therapy is increasingly considered for myopia control, particularly when a child shows ongoing progression despite monotherapy.
  2. Not all children with progressing myopia require combination therapy; many can be effectively managed with monotherapy.
  3. Children at higher risk for myopia progression include those who are younger, have rapid axial elongation, or a strong family history.
  4. Before initiating combination therapy, clinicians should audit treatment adherence and effectiveness to confirm true progression.
  5. Evidence suggests combination therapy may be beneficial, but it should not be viewed as a universal next step for all patients.
...more

The Ophthalmologist

  • August 14, 2026
Santen Joins Global Eye Health Summit
  • August 14, 2026
  • 2 min
  1. Santen Pharmaceutical has joined the inaugural Global Summit for Eye Health as a High Impact Partner.
  2. The summit, organized by IAPB and WHO, will take place in Antigua and Barbuda on November 2, 2026.
  3. Participants will launch the Global Eye Health Compact to accelerate progress through measurable commitments.
  4. Santen plans to unveil its global eye health commitment at the summit to support improvements in eye health.
  5. Over one billion people live with avoidable vision impairment, necessitating coordinated action across various sectors.
...more

Frontiers In Neurology

  • August 14, 2026
Influence of Environmental Factors on Neurotoxicity: The Impact of Heavy Metals in Neurological Conditions
  • Snehashis Mandal
  • Priti Dipa
  • Neha
  • Dhrita Chatterjee
  • Kousik Maparu
  • August 14, 2026

Get a structured, in-depth report that distills clinical articles into clear insights, data, and analysis for deeper learning.

Read Full Report

Frontiers In Psychiatry

  • August 14, 2026
The Frustration Tolerance Breakdown Theory in Substance Use Disorders
  • Yorkiris Mármol Contreras
  • Rocio Sanchez Rivas
  • Shaina Banh
  • Iona C. Duncan
  • Sindhuja Earagolla
  • Thomas A. Green
  • August 14, 2026
  1. Individuals with substance use disorders (SUDs) often continue drug-seeking despite significant frustrations that typically deter others.
  2. The frustration brake failure hypothesis posits that frustration fails to moderate motivation in certain individuals with SUDs.
  3. Frustration serves a biphasic role in drug-seeking behavior, enhancing motivation at low levels and diminishing it at high levels for those without SUDs.
  4. The proposed therapeutic approach aims to target neurobiological mechanisms to restore frustration's role in reducing drug-seeking motivation.
  5. Existing hypotheses on SUDs, like the CNDS and incentive sensitization hypotheses, do not adequately address the role of frustration in motivation.
...more